Exanta Oral & Sub-Q Cleared In France; U.S. NDA Seeks Oral Formulation Only
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Proposed European labeling for AstraZeneca’s anticoagulant Exanta does not call for regular liver monitoring.
You may also be interested in...
AstraZeneca Exanta "not approvable"
AstraZeneca's anticoagulant Exanta (ximelagatran) is "not approvable," the company announces Oct. 8. The agency's decision, reached two weeks ahead of the Oct. 23 user fee date, is in line with the Cardiovascular & Renal Drugs Advisory Committee's Sept. 10 recommendation against approval for all three indications being sought. Liver safety has been a key safety concern with Exanta; AstraZeneca previously indicated that labeling would likely include requirements for regular liver function monitoring (1Pharmaceutical Approvals Monthly Jan. 1, 2004, p. 17). During an Oct. 6 conference call, VP Hamish Cameron described the situation as "a clash between what might be termed regulatory medicine and clinical medicine"...
Year-End Submissions Total 17, Including Four From Aventis
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.
Year-End Submissions Total 17, Including Four From Aventis
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.